Reata Pharmaceuticals

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases.

Reata focuses on drugs with novel mechanisms of action that modulate important regulatory proteins, called transcription factors, that coordinate the cellular response to stressors by activating or suppressing the activity of many target proteins.

Revenue(FY, 2016)

$49.9 M

Market capitalization(2017-08-18)

$588 M

Company Growth (employees)

Type

Public

Irving, US

Founded

2002

Size (employees)

75 (est)+18%

Website

reatapharma.com

Reata Pharmaceuticals was founded in 2002 and is headquartered in Irving, US

Key People at Reata Pharmaceuticals

Warren Huff

President and CEO

Reata Pharmaceuticals Office Locations

Reata Pharmaceuticals has an office in Irving

Irving, US (HQ)

150 2801 Gateway Dr

Reata Pharmaceuticals Data and Metrics

Reata Pharmaceuticals Financial Metrics

Reata Pharmaceuticals's revenue was reported to be $49.9 m in FY, 2016 which is a 1% decrease from the previous period.

Summary

USD

Reata Pharmaceuticals's current market capitalization is $588 m.

Source: SEC Filings

Income Statement

USD	FY, 2015	FY, 2016
Revenue	50.3 m	49.9 m
Revenue growth, %		(1%)
R&D expense	35.1 m	39.5 m
General and administrative expense	13.7 m	16.6 m
Operating expense total	50.7 m	56.7 m
Pre tax profit	(302 k)	(6.7 m)
Income tax expense	1.1 m	(441 k)
Net Income	(1.5 m)	(6.2 m)

Source: SEC Filings

Balance Sheet

Annual

USD	FY, 2015	FY, 2016
Cash	42 m	84.7 m
Inventories		2.6 m
Current Assets	77.3 m	87.3 m
PP&E	1.1 m	819 k
Total Assets	80 m	89.1 m
Accounts Payable		3.8 m
Current Liabilities	60.8 m	59.6 m
Non-Current Liabilities	291.3 m	244.5 m
Total Liabilities	352.1 m	304.1 m
Additional Paid-in Capital	10 m	74.3 m
Retained Earnings	(283.1 m)	(289.4 m)
Total Equity	(273.2 m)	(215 m)
Financial Leverage	-0.3 x	-0.4 x

Quarterly

USD	Q2, 2016	Q3, 2016	Q1, 2017
Cash	92.4 m	95.7 m	82.7 m
Current Assets	112.9 m	99.9 m	85.7 m
PP&E	942 k	899 k	703 k
Total Assets	114.4 m	101.8 m	88.2 m
Accounts Payable	1.6 m	1.3 m	541 k
Current Liabilities	60 m	60.1 m	51.2 m
Non-Current Liabilities	266.6 m	254 m	257.3 m
Additional Paid-in Capital	72.2 m	73 m	76.3 m
Retained Earnings	(284.3 m)	(285.2 m)	(296.6 m)

Cash Flow

USD	FY, 2015	FY, 2016
Net Income	(1.5 m)	(6.2 m)
Depreciation and Amortization	1.8 m	682 k
Inventories		(1.2 m)
Accounts Payable		299 k
Cash From Operating Activities	(44.6 m)	(19.3 m)
Purchases of PP&E	(272 k)	(340 k)
Cash From Investing Activities	(260 k)	(339 k)
Cash From Financing Activities	(870 k)	62.3 m
Income Taxes Paid		1.2 m